Mind over matter: exercise and meditation may soothe chemo nerve damage
NCT ID NCT07556965
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a program combining exercise and mindfulness-based therapy can reduce nerve pain and emotional distress in cancer patients who have nerve damage from chemotherapy. About 40 adults with early-stage cancer and chemotherapy-induced peripheral neuropathy will follow a structured exercise and mindfulness routine for several weeks. Researchers will track changes in physical symptoms, psychological distress, and quality of life to see if this non-drug approach offers relief.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with a pathologically confirmed malignant tumor; * Currently receiving neurotoxic chemotherapy and experiencing chemotherapy-induced peripheral neuropathy (CIPN); * Cancer stage Tis or stage I-III; * Aged 18 years or older, with normal consciousness, mental status, and verbal communication ability; able to understand and judge their own sensations and general condition; and able to complete the questionnaires; * Willing to participate in the study and able to provide written informed consent; * Patients with NCI-CTCAE grade \<2 who are considered suitable for exercise intervention. Exclusion Criteria: * Presence of other neurological diseases or severe psychiatric disorders; * Presence of other serious illnesses, such as severe heart disease or respiratory failure; * Inability to understand or complete the questionnaires; * Participation in psychological counseling, psychotherapy, or other clinical trials within the past 6 months; * Inability or expected inability to complete the full 6-week intervention.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer patients are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can TENS, compression, or cold therapy stop chemo nerve pain?
- Can an antidepressant calm Chemotherapy's nerve pain?
- Retraining the senses to fight chemotherapy nerve damage
- Retraining the senses to fight chemotherapy nerve damage
- Which PICC insertion method causes fewest complications?
- Chilling out Chemo's side effects: could cold therapy shield nerves?